---
title: "Chengda Pharmaceuticals Co.,Ltd. (301201.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301201.SZ.md"
symbol: "301201.SZ"
name: "Chengda Pharmaceuticals Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:24:36.851Z"
locales:
  - [en](https://longbridge.com/en/quote/301201.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301201.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301201.SZ.md)
---

# Chengda Pharmaceuticals Co.,Ltd. (301201.SZ)

## Company Overview

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.chengdapharm.com](https://www.chengdapharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.44)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 126 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 48.54% |  |
| Net Profit YoY | 92.68% |  |
| P/B Ratio | 2.86 |  |
| Dividend Ratio | 0.50% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6029072657.51 |  |
| Revenue | 459119271.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -0.17% | D |
| Profit Margin | -0.77% | D |
| Gross Margin | 33.13% | C |
| Revenue YoY | 48.54% | A |
| Net Profit YoY | 92.68% | A |
| Total Assets YoY | -2.40% | D |
| Net Assets YoY | -1.88% | D |
| Cash Flow Margin | -1293.09% | E |
| OCF YoY | 48.54% | A |
| Turnover | 0.19 | D |
| Gearing Ratio | 9.78% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Chengda Pharmaceuticals Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "48.54%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "92.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.86",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.50%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6029072657.51",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "459119271.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-0.17%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.77%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "33.13%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "48.54%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "92.68%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.40%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.88%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-1293.09%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "48.54%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "9.78%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1707.89 | 222/215 | - | - | - |
| PB | 2.86 | 133/215 | 3.10 | 2.77 | 1.97 |
| PS (TTM) | 13.13 | 197/215 | 17.51 | 14.51 | 12.72 |
| Dividend Yield | 0.50% | 131/215 | 0.72% | 0.52% | 0.46% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301201.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301201.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301201.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301201.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**